Patents Assigned to Dorian Therapeutics, Inc.
  • Publication number: 20210290680
    Abstract: The disclosure provides methods and compositions for modulating cellular aging comprising contacting a cell with an inhibitor of USP16. The disclosed methods may be used to improve the efficacy of cell-based therapies, including chimeric antigen receptor (CAR)-T cell therapies, engineered T cell receptor (TCR) therapies, natural killer (NK) cell therapies, hematopoietic stem cell-based therapies, and other adoptive cell therapies.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 23, 2021
    Applicant: Dorian Therapeutics, Inc.
    Inventors: Benedetta NICOLIS DI ROBILANT, Maddalena ADORNO